NMDA Receptor

Previous studies with Lanicemine and ketamine demonstrated that both compounds bind with low-to-moderate affinity to sites within the NMDA channel pore, exhibit strong voltage dependence, and have similar lack of NR2A vs NR2B subunit selectivity (Table 1). However, at steady-state concentrations, ketamine had a greater propensity to be trapped within the NMDA channel pore following the removal and reapplication of glutamate (trapping: 86% with ketamine vs 54% with Lanicemine). Low trapping theoretically preserves use-dependent channel block under conditions of normal, pyramidal cell-driven, synaptic transmission. Thus, while NMDARs are ubiquitously expressed within the central nervous system, the low-trapping property of lanicemine may bias channel block to those elements of the brain, such as cortical interneurons, with high levels of tonic activity. Since selective reduction in NMDAR activity on cortical interneurons has been shown to increase spontaneous, high-frequency (gamma-band ∼40 Hz) EEG gamma-band EEG may serve as a useful biomarker for NMDA channel blockers in general and lanicemine in particular. [1]

Minimal psychotomimetic side effects are associated with lanisemin's prolonged antidepressant efficacy [1]. In addition to activating the brain circuits responsible for producing gamma electroencephalography (EEG), lanisemin (3, 10, or 30 mg/kg; i.p.) also modifies these networks separately from the more generalized system-level disturbances that are commonly associated with ketamine [ 1].

---

Using quantitative electroencephalography (qEEG) to objectively align doses of a low-trapping NMDA channel blocker, AZD6765 (Lanicemine), to that of ketamine, we demonstrate the potential for NMDA channel blockers to produce antidepressant efficacy without psychotomimetic and dissociative side effects. Furthermore, using placebo-controlled data, we show that the antidepressant response to NMDA channel blockers can be maintained with repeated and intermittent drug administration. Together, these data provide a path for the development of novel glutamatergic-based therapeutics for treatment-refractory mood disorders. [1]

---

---

EEG, physiological and dissociative effects of Lanicemine relative to ketamine in human [1]
To determine whether the differentiated EEG/side-effect profile seen preclinically with ketamine and lanicemine translates to humans, we conducted the qEEG crossover study in healthy volunteers. Out of 23 subjects randomized, 14 subjects were treated with lanicemine 75 mg, 19 with lanicemine 150 mg, 17 with ketamine and 15 with placebo. The study was stopped earlier than planned following two serious adverse events (syncope due to orthostatic hypotension) occurring during ketamine infusion. Significant increases in gamma-band EEG were observed at the stop of infusion for both ketamine and lanicemine, and baseline-corrected gamma-EEG following 150 mg lanicemine was statistically indistinguishable from ketamine (0.5 mg kg−1) (Figure 2, left and top right). In addition, both ketamine and the 150-mg dose of lanicemine produced significant reductions in prefrontal theta-cordance, a derived EEG biomarker putatively linked to early antidepressant treatment response (Figure 2, left) There were no serious adverse events associated with lanicemine.

---

Single-dose (100 mg) exploratory safety and efficacy trial of Lanicemine in patients with treatment-resistant MDD [1]
Translational and previous preclinical data28 suggested a psychotomimetic-free therapeutic window for lanicemine in humans at doses of 75–150 mg. We therefore conducted a pilot study to determine whether a dose in this range (100 mg) might be relatively well tolerated and yet still provide an antidepressant signal. In a phase IIA monotherapy study (study 1), 34 treatment-resistant patients (mean HAM-D-17 score ∼25; Supplementary Table 1) were randomized to a single infusion of lanicemine 100 mg i.v. (n=16 (7, male; 9, female)) or placebo (n=18 (7, male; 11, female)).

---

Adjunctive, multiple-infusion efficacy trial of Lanicemine in patients with moderate-to-severe MDD and a history of poor response to antidepressants [1]
On the basis of the exploratory data from study 1, a second phase II study (study 9) was designed to determine whether repeated administration of lanicemine over 3 weeks at an interval of three infusions per week would consolidate and extend the therapeutic benefits observed from a single administration. In study 9, we examined the effect of augmenting patients' existing antidepressant therapies with repeated lanicemine administration on symptom improvement in outpatients with moderate-to-severe MDD with a history of poor response to multiple antidepressants. Infusions were stopped after 3 weeks to explore the durability of the antidepressant effect over a subsequent 5-week observation period in which drug was not administered.

Animal/Disease Models: Male SD (SD (Sprague-Dawley)) rat [1]
Doses: 3, 10 or 30 mg/kg
Route of Administration: intraperitoneal
Experimental Results: Spontaneous gamma-band EEG produced significant dose-dependent elevations, but only with ketamine Gamma changes are closely associated with increases in locomotor activity.

---

Effects of ketamine and Lanicemine on EEG in rodent models [1]
Male Sprague-Dawley rats (n=6–9) were implanted with frontal and temporal skull screw electrodes for continuous EEG recording and trained to perform a single-tone operant discrimination task for food reward. EEG was recorded and behavioral performance was evaluated for a 30-min period before dosing and for three 30-min periods following dosing with intraperitoneal lanicemine (3, 10 or 30 mg kg−1), ketamine (1, 3, 10 or 30 mg kg−1) or vehicle control. EEG data acquired by Neuralynx were imported to NeuroExplorer Ver. 3.183 software suite. Consecutive 10-s epochs of EEG data from each channel were subjected to a fast Fourier transform, from which EEG power density was computed from 1 to 50 Hz.

---

Lanicemine studies in human [1]
All studies in man were approved by the institutional review boards at each site and were conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and the International Conference on Harmonization guideline E6: Good Clinical Practice. All participants provided written, informed consent before study entry and had the right to withdraw from the study at any time.

---

EEG, physiological and dissociative effects of Lanicemine relative to ketamine in human (phase I, D2285M00008/NCT01130909) [1]
A phase I, randomized, double-blind, four-way, crossover study in healthy subjects was performed at a single center in France between May 2010 and January 2011 (D2285M00008/NCT01130909). Males aged 30–45 years, with body mass index 18–30 kg m−2 and non-smoking status for at least 4 weeks, without clinically relevant acute or chronic disease, received lanicemine 75 mg, lanicemine 150 mg, ketamine 0.5 mg kg−1 or placebo as single intravenous (i.v.) administrations. Washout was ⩾7 days between study periods.

---

Single-dose (100 mg) exploratory safety and efficacy trial of Lanicemine in patients with treatment-resistant MDD (phase IIA, D6702C00001/NCT00491686) [1]
The phase IIA, double-blind, randomized study (D6702C00001/NCT00491686; study 1) was performed at five centers in the United States between July 2007 and November 2007. It consisted of a screening period (⩽30 days), one inpatient treatment period, and one follow-up visit 7–10 days after treatment. Outpatients (men and women) aged 21–65 years with DSM-IV-TR-diagnosed MDD, confirmed by the MINI, a history of poor response to ⩾2 antidepressants, and baseline Hamilton Rating Scale for Depression (HAM-D-17) score ⩾20 were eligible. Exclusion criteria included: current episode of depression ⩽12 weeks or ⩾5 years; history of DSM-IV Axis I disorder other than MDD or substantial Axis II disorder; use of mood stabilizers, other antipsychotic or psychoactive drugs within 7 days of day 1 or fluoxetine or monoamine oxidase inhibitors within 14 days of day 1 of the treatment period; and evidence of other clinically relevant disease.

Lanicemine 100 mg or placebo (0.9% saline) was administered as single i.v. infusions (30 ml volume over 60 min). The primary efficacy evaluation was change in Montgomery-Åsberg Depression Rating Scale (MADRS) total score from baseline to 24 h post infusion. Secondary variables included: change in MADRS total score at other scheduled time points; Bond-Lader Visual Analogue Scale; Brief Psychiatric Rating Scale; and CogState (CogState, Melbourne, Australia). Safety evaluations included: adverse events, vital signs, physical examination, clinical laboratory evaluations and electrocardiograms.

---

Adjunctive, multiple-infusion efficacy trial of Lanicemine in patients with moderate-to-severe MDD and a history of poor response to antidepressants (phase IIB, D6702C00009/NCT00781742) [1]
The phase IIB, double-blind, randomized, outpatient study (D6702C00009/NCT00781742; study 9) was performed at 30 centers in the United States between October 2008 and March 2010. It consisted of a screening period (⩽30 days), a 3-day placebo run-in (when patients received one single-blind placebo infusion (0.9% saline)), and a 3-week treatment period, followed by a 5-week treatment-free follow-up.

Patients were randomized in a 1:1:1 ratio to Lanicemine 100 mg, lanicemine 150 mg or placebo (three i.v. infusions per week) as adjunct to ongoing psychotropics that included at least one antidepressant. The predefined primary efficacy variable was change from randomization to week 3 in MADRS total score. Secondary variables included: MADRS score change at other scheduled assessments; remission (that is, MADRS score ⩽10); response (that is, ⩾50% reduction from baseline in MADRS score); Hamilton Rating Scale for Anxiety (HAM-A; anxiety); HAM-D-17 and QIDS-SR-16 (depressive symptoms); CGI-S and Clinical Global Impression of Improvement (CGI-I; global improvement); and Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q; quality of life). Efficacy evaluations were performed at weekly intervals from baseline (randomization) to week 8. Changes in QIDS-SR-16 score at day 1 and MADRS score at day 3 were also measured to assess onset of effect.

Change from baseline in MADRS total score and continuous secondary efficacy variables were compared between the two Laniceminegroups and placebo at week 3 with LOCF in the ITT analysis set, using an analysis of covariance model with baseline MADRS total score as a covariate, with treatment, MDD disease severity and comorbid generalized anxiety disorder status as fixed effects, and pooled center as a random effect. A logistic regression model including treatment and baseline in the model was used for categorical secondary efficacy variables.

An exploratory safety and efficacy trial of a single dose (100 mg) of lannicillin in patients with treatment-resistant major depressive disorder [1]
Translational studies and prior preclinical data suggest that lannicillin has a psychoactive therapeutic window in the human dose range of 75–150 mg. Therefore, we conducted a pilot study to determine whether this dose range (100 mg) is relatively well tolerated while still providing an antidepressant signal. In a phase IIA monotherapy study (Study 1), 34 patients with treatment-resistant depression (mean HAM-D-17 score of approximately 25; see Supplementary Table 1) were randomized to receive a single intravenous infusion of 100 mg lannicillin (n=16 (7 men; 9 women)) or placebo (n=18 (7 men; 11 women)).
Lannicillin 100 mg was generally well tolerated, with dizziness being the most common adverse event (Supplementary Table 2). Lannicilamine had no clinically significant effect on psychotic-like symptoms assessed by the Brief Psychiatric Rating Scale (BPRS) (1-hour mean ± standard error: 22.8 ± 1.1 in the lannicilamine group vs. 23.9 ± 1.2 in the placebo group; 4-hour mean ± standard error: 23.1 ± 1.2 in the lannicilamine group vs. 24.4 ± 1.5 in the placebo group), dissociative symptoms assessed by the CADSS (1-hour least squares mean (LSM) ± standard error: 0.6 (0.59) in the lannicilamine group vs. -0.8 (0.55) in the placebo group), or cognitive function assessed by the CogState (Supplementary Figures 1 and 2). No serious adverse events were reported during treatment. At the 24-hour time point, we did not observe a statistically significant difference in changes in MADRS scores between the lannicilamine and placebo groups. However, the placebo effect was significant at this point (e.g., a 14.2-point change in MADRS score), making the larger numerical change (2.44, P=0.472) between the lannicillin and placebo groups, though not statistically significant, difficult to interpret. Nevertheless, we observed statistically significant differences in MADRS scores between the lannicillin and placebo groups at 1 hour and 72 hours post-infusion (according to the presupposed criteria of this exploratory study) (P=0.183 and 0.089, respectively) (Supplementary Figure 3). Furthermore, changes in the Bond-Rad Visual Analogue Scale (VAS) for sadness/happiness at 4 hours also suggested an antidepressant-like effect (P=0.137). The antidepressant effect of lannicillin peaked at 72 hours (a 5.7-point reduction in MADRS score compared to the placebo group, P=0.089) and gradually subsided over 10–13 days after a single intravenous infusion, but remained on average 10 points lower than baseline.
Safety assessment included safety and tolerability evaluation, adverse events, pupil size and electronystagmography, and subjective separation effect assessed using the 27-item clinician-managed separation state scale (CADSS). Optokinetic parameters were measured using a Metrovision MON 2008H at 25 minutes after infusion initiation, and CADSS was assessed at pre-defined time points within 8 hours of infusion initiation.

[1]. Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacywith minimal psychotomimetic adverse effects. Mol Psychiatry. 2014 Sep;19(9):978-85.

Lannicilamine has been used in clinical trials for the treatment and basic science of depression, major depressive disorder, and treatment-resistant major depressive disorder. Interest in developing glutamatergic drugs, particularly NMDAR antagonists, for the treatment of severe mood disorders is rapidly growing. Here, we report that a low-capture NMDA channel blocker, lannicilamine (100 mg), has significant and durable antidepressant effects without the significant dissociative side effects observed with ketamine at this dose. Completed lannicilamine studies to date cover the largest cohort of patients with depression (n>120) treated with NMDA channel blockers to date, rigorously testing the hypothesis that NMDAR antagonists exert antidepressant efficacy independently of psychiatric side effects. Secondly, while data from Study 1 and Zarate et al. provide evidence supporting the antidepressant effect of a single dose of lannicilamine, a similar single-dose trend was not observed in Study 9. Given that Study 9 (unlike Study 1) was an adjunctive therapy study, and that most reports on ketamine to date have been monotherapy studies, the extent to which concomitant medication (i.e., benzodiazepines) alters the onset time of NMDA channel blocker antidepressant efficacy remains an open question. Preliminary reports on adjunctive therapy with ketamine and antidepressants also suggest a delayed onset of action. Finally, while Study 9 provides limited data on the efficacy and safety of repeated intermittent dosing, a better characterization and understanding of the long-term safety and efficacy profiles of NMDA channel blockers, including ranicillin, is crucial. These questions, along with other related issues, are being explored in ongoing research (e.g., Study 31: ClinicalTrials.gov registration number: NCT01482221). Ranicillin is a low-NMDA channel blocker that has shown antidepressant effects in patient studies and, at doses causing similar cortical activation changes, exhibits fewer dissociative and psychotic-like symptoms than ketamine. In clinical studies, lanicillin showed significant efficacy with no obvious clinical dissociation symptoms or psychotic-like side effects. These data are consistent with the pharmacological dissociation of efficacy and psychotic-like side effects observed in preclinical and phase I studies. Importantly, in a 3-week placebo-controlled phase IIB study of patients with moderate to severe depression, repeated infusions of lanicillin (100 or 150 mg every 3 days) maintained antidepressant efficacy without psychotic-like side effects. These results suggest that NMDA channel blockers can achieve antidepressant effects without obvious psychotic-like effects and can maintain efficacy with repeated administration. Ongoing clinical trials are exploring the potential antidepressant properties of lanicillin. [1]

C13H14N2

198.26

198.115

C, 78.75; H, 7.12; N, 14.13

190581-71-6

(Rac)-Lanicemine;61890-25-3;Lanicemine;153322-05-5

10198092

Typically exists as solid at room temperature

1.7

1

2

3

15

175

1

C1=CC=C(C=C1)[C@@H](CC2=CC=CC=N2)N

FWUQWDCOOWEXRY-CYBMUJFWSA-N

InChI=1S/C13H14N2/c14-13(11-6-2-1-3-7-11)10-12-8-4-5-9-15-12/h1-9,13H,10,14H2/t13-/m1/s1

(1R)-1-phenyl-2-pyridin-2-ylethanamine

(R)-Lanicemine; 190581-71-6; CHEMBL466285; SCHEMBL13557819; (1R)-1-phenyl-2-pyridin-2-ylethanamine; (1R)-1-phenyl-2-(pyridin-2-yl)ethan-1-amine; .

2934.99.9001

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples

Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.

---

Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)
*Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution.
Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline)
Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil)
Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals).

View More

Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)]
*Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.
Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline)
Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline)
Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline)
Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline
Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil)
Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline)

---

Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium)
Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose
Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals).

View More

Oral Formulation 3: Dissolved in PEG400
Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose
Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose
Oral Formulation 6: Mixing with food powders

---

Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently.

---

 (Please use freshly prepared in vivo formulations for optimal results.)